3,5-Dinitrocatechol

DB02105

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 200.1058
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

69 Data
Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with 3,5-Dinitrocatechol.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with 3,5-Dinitrocatechol.
Metoclopramide The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Metoclopramide.
Ziprasidone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Ziprasidone.
Olanzapine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Olanzapine.
Clozapine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Clozapine.
Risperidone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Risperidone.
Quetiapine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Quetiapine.
Aripiprazole The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Aripiprazole.
Paliperidone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Paliperidone.
Bifeprunox The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Bifeprunox.
Iloperidone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Iloperidone.
Cariprazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Cariprazine.
Lumateperone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Lumateperone.
Sertindole The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Sertindole.
Asenapine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Asenapine.
Lurasidone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Lurasidone.
Perospirone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Perospirone.
Brexpiprazole The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Brexpiprazole.
Blonanserin The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Blonanserin.
Melperone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Melperone.
Zotepine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Zotepine.
Brilaroxazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Brilaroxazine.
Amisulpride The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Amisulpride.
Pipamperone The therapeutic efficacy of Pipamperone can be decreased when used in combination with 3,5-Dinitrocatechol.
Loxapine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Loxapine.
Promazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Promazine.
Prochlorperazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Prochlorperazine.
Droperidol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Droperidol.
Chlorpromazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Chlorpromazine.
Haloperidol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Haloperidol.
Fluphenazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Fluphenazine.
Thioridazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Thioridazine.
Trifluoperazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Trifluoperazine.
Perphenazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Perphenazine.
Mesoridazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Mesoridazine.
Pimozide The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Pimozide.
Chlorprothixene The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Chlorprothixene.
Methotrimeprazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Methotrimeprazine.
Periciazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Periciazine.
Molindone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Molindone.
Thioproperazine The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Thioproperazine.
Thiothixene The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Thiothixene.
Zuclopenthixol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Zuclopenthixol.
Azaperone The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Azaperone.
Diethylstilbestrol The metabolism of Diethylstilbestrol can be decreased when combined with 3,5-Dinitrocatechol.
Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with 3,5-Dinitrocatechol.
Norepinephrine The metabolism of Norepinephrine can be decreased when combined with 3,5-Dinitrocatechol.
Epinephrine The metabolism of Epinephrine can be decreased when combined with 3,5-Dinitrocatechol.
Dobutamine The metabolism of Dobutamine can be decreased when combined with 3,5-Dinitrocatechol.
Methyldopa The metabolism of Methyldopa can be decreased when combined with 3,5-Dinitrocatechol.
Dopamine The metabolism of Dopamine can be decreased when combined with 3,5-Dinitrocatechol.
Micafungin The metabolism of Micafungin can be decreased when combined with 3,5-Dinitrocatechol.
Quercetin The metabolism of Quercetin can be decreased when combined with 3,5-Dinitrocatechol.
Echinacoside The metabolism of Echinacoside can be decreased when combined with 3,5-Dinitrocatechol.
Phenytoin The metabolism of Phenytoin can be decreased when combined with 3,5-Dinitrocatechol.
Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with 3,5-Dinitrocatechol.
Apomorphine The metabolism of Apomorphine can be decreased when combined with 3,5-Dinitrocatechol.
Estradiol The metabolism of Estradiol can be decreased when combined with 3,5-Dinitrocatechol.
Isoprenaline The metabolism of Isoprenaline can be decreased when combined with 3,5-Dinitrocatechol.
Tranylcypromine The risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Tranylcypromine.
Phenelzine The risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Phenelzine.
Isocarboxazid The risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Isocarboxazid.
Iproniazid The risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Iproniazid.
Nialamide The risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Nialamide.
Safrazine The risk or severity of adverse effects can be increased when 3,5-Dinitrocatechol is combined with Safrazine.
Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with 3,5-Dinitrocatechol.
Flupentixol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Flupentixol.
Aripiprazole lauroxil The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Aripiprazole lauroxil.

Target Protein

Catechol O-methyltransferase COMT

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul